GlobeNewswire06.10.19
electroCore Inc., a commercial-stage bioelectronic medicine company, announced that Frank R. Amato will be stepping down as CEO. Amato joined electroCore in 2012 and was named CEO in July 2016. The Board has initiated a search for a successor, and Amato will remain for a transition period.
“Under Frank’s leadership, electroCore made tremendous progress, including successfully navigating our initial public offering and transitioning to a commercial stage company with a novel technology targeting three high-value, difficult to treat headache indications,” said Carrie S. Cox, Chairman of the Board. “On behalf of the Board, I would like to thank Frank for his contributions as we established a foundation to drive future growth, and I wish him the very best in his future endeavors. We have immediately initiated a search for Frank’s successor, and we are committed to ensuring a seamless transition.”
“Under Frank’s leadership, electroCore made tremendous progress, including successfully navigating our initial public offering and transitioning to a commercial stage company with a novel technology targeting three high-value, difficult to treat headache indications,” said Carrie S. Cox, Chairman of the Board. “On behalf of the Board, I would like to thank Frank for his contributions as we established a foundation to drive future growth, and I wish him the very best in his future endeavors. We have immediately initiated a search for Frank’s successor, and we are committed to ensuring a seamless transition.”